Fred Aslan, Artiva Biotherapeutics CEO
Artiva refiles for IPO three years after original plans in a vastly different environment
Artiva Biotherapeutics, a clinical-stage NK cell therapy biotech, is trying again for the public markets, it revealed Friday afternoon in an SEC
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
